Paul Kristjansen
Paul Kristjansen is responsible for the Frontier Grants, a grant initiative to facilitate transitions from basic research to attractive prospects for biotech investors.
Paul joined the Lundbeck Foundation in August 2022 after more than 5 years in Business Development at Lundbeck A/S, successfully heading in-licensing and M&A projects.
Paul has extensive experience in research and clinical development at the University of Copenhagen, Harvard University, and in the Danish pharmaceutical industry. He has had leading responsibilities within R&D at the University of Copenhagen, Novo Nordisk, and Lundbeck A/S, especially within oncology, autoimmunity, and brain diseases with expertise in early drug development and translational disease models.
Paul holds a MD, PhD, DMSc from University of Copenhagen.
